KC1086 not checked

Beijing Konruns Pharmaceutical Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Dosage: based on the doses selected in Part 1 (high dose and low dose); Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.”In the company’s words, NCT07937605 on ClinicalTrials.gov
Tested for
HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer, Advanced Solid Tumors Cancer
Main trialPhase 2
“The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of KC1086 in combination with fulvestrant in adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer.”In the company’s words, NCT07937605 on ClinicalTrials.gov

Other drugs for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

All 397 drugs for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Coming up2

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Nov 2029 KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer
Phase 1Not yet recruiting Aug 2028 A Study of KC1086 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow KC1086

Following is part of Solo: you see every change to KC1086 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in